Mapping Racial Capitalism: Implications for Law

The theory of racial capitalism offers insights into the relationship between class and race, providing both a structural and a historical account of the ways in which the two are linked in the global economy. Law plays an important role in this. This article sketches what we believe are two key structural features of racial capitalism: profit-making and race-making for the purpose of accumulating wealth and power. We understand profit-making as the extraction of surplus value or profits through processes of exploitation, expropriation, and expulsion, which are grounded in a politics of race-making. We understand race-making as including racial stratification, racial segregation, and the creation of sacrifice zones, which reflect the strategies and outcomes of profit-making. The structural features of racial capitalism thus are mutually constitutive: profit-making processes create and reinforce the making of racial meaning, while race-making, underwritten by white supremacy, structures and facilitates the economic processes of profit-making. Together, they constitute a global system dependent on the unbridled extraction of wealth from both humans and nature

Species distribution and antifungal sensitivity patterns of vaginal yeasts

Objectives: To identify yeast isolates in vaginal specimens to species level and determine their antifungal susceptibility patterns.Design: Cross-sectional laboratory-based study.Setting: The Aga Khan University Hospital (AKUH), Nairobi.Subjects: Yeast isolates from high vaginal swabs presented to the laboratory for culture and sensitivity were identified to species level using the API Candida system and subjected to broth microdilution susceptibility testing.Main outcome measures: Frequency tables and graphs were used to summarise the data. Susceptibility data was analysed by the non-parametric Fisher’s exact test. P0.05) between the susceptibility of C.albicans and non-albicans isolates to flucytosine and amphotericin B, however there was a significant difference (

Sensitivity And Specificity Of Hiv Rapid Tests Used For Research And Voluntary Counselling And Testing

Background: HIV rapid tests (RT) are a quick and non-technically demanding means to perform HIV voluntary counselling and testing (VCT) but understanding their limitations is vital to delivering quality VCT. Objective: To determine the sensitivity and specificity of HIV rapid tests used for research and voluntary counselling and testing at four sites in East Africa. Design: Cross-sectional study. Setting: Masaka District, Uganda; a sugar plantation in Kakira, Uganda; Coastal Villages in the Kilifi District of Kenya; and the Urban slum of Kangemi located West of Nairobi, Kenya. Subjects: Six thousands two hundred and fifty five consenting volunteers were enrolled into the study, and 675 prevalent HIV infections were identified. Results: The RT sensitivity tended to be high for all assays at all sites (97.63-100%) with the exception of the Uni-Gold assay (90.24% in Kangemi, 96.58% in Kilifi). Twenty four RT results were recorded as ‘weak positives\', 22 (92%) of which were negative by ELISA. There was a high rate of RT false positives in Uganda (positive predictive values ranging from 45.70% to 86.62%). Conclusions: The sensitivity and specificity of the RT varied significantly across sites. The rate of RT misclassification in Uganda suggests that a multiple test algorithm may be preferable to a single test as screener for HIV VCT. East African Medical Journal Vol. 85 (10) 2008: pp. 500-50

Food safety in the East African Community countries: Perceptions of key stakeholders in the food value chain

Introduction: Five of the six countries in the East Africa Community are classified by the WHO under the AFR-E sub-region. This sub-region is the second highest in foodborne disease burden with 1,200 DALYs per 100,000 inhabitants. Unsafe food has serious impacts on health and livelihoods of the people, as well as trade and economic development. Addressing food safety gaps requires participation of all stakeholders in the food value chain. Objectives: The objective of this study is to analyse the perceptions of relevant stakeholders on status of food safety, food safety gaps in informal markets and discuss opportunities to improve food safety in the region. Materials and methods: This is a qualitative study involving the use of participatory methods. Burundi and Kenya have purposely been selected for the study, with defined informal market settings. The protocols to guide data collection will be developed in English and translated to Swahili (for Kenya) and Kirundi (for Burundi), and pre-tested before use in the field. Ethical approvals in line with requirements in each country will be sought. Informed consent will also be obtained from all participants prior to their involvement in the study. Data will be summarized and synthesized thematically. Statistical methods for handling non-normal data will be considered. Results: The perceptions of stakeholders on status of food safety in informal markets and suggestions on priority value chains that should be considered for food safety intervention will be discussed. Conclusions: This study will provide in-depth understanding of food safety status in both countries, as perceived by the stakeholders. The findings are expected to guide future research work and further inform decision making for policy development and donor investment

Prevalence of uncontrolled hypertension in people with comorbidities in sub-Saharan Africa : a systematic review and meta-analysis

Background: The burden of uncontrolled hypertension in sub-Saharan Africa (SSA) is high and hypertension is known to coexist with other chronic diseases such as kidney disease, diabetes among others. This is the first systematic review and meta-analysis to determine the burden of uncontrolled hypertension among patients with comorbidities in SSA. Methods: A comprehensive search was conducted on MEDLINE, Excerpta Medica Database (Embase) and Web of Science to identify all relevant articles published between 1 January 2000 and 17 June 2021. We included studies that reported on the prevalence of uncontrolled hypertension among people in SSA who report taking antihypertensive treatment and have another chronic condition. A random-effects meta-analysis was performed to obtain the pooled estimate of the prevalence of uncontrolled hypertension among patients with comorbid conditions while on treatment across studies in SSA. Results: In all, 20 articles were included for meta-analyses. Eleven articles were among diabetic patients, five articles were among patients with HIV, two were among patients with stroke while chronic kidney disease and atrial fibrillation had one article each. The pooled prevalence of uncontrolled hypertension among patients with comorbidities was 78.6% (95% CI 71.1% to 85.3%); I² 95.9%, varying from 73.1% in patients with stroke to 100.0% in patients with atrial fibrillation. Subgroup analysis showed differences in uncontrolled hypertension prevalence by various study-level characteristics Conclusion: This study suggests a high burden of uncontrolled hypertension in people with comorbidities in SSA. Strategies to improve the control of hypertension among people with comorbidities are needed. PROSPERO registration number: CRD42019108218

Survey data on income, food security, and dietary behavior among women and children from households of differing socio-economic status in urban and peri-urban areas of Nairobi, Kenya

This article describes data collected to analyze consumer behaviors in vulnerable populations by examining key access constraints to nutritious foods among households of differing socio-economic status in urban and peri‑urban areas of Nairobi, Kenya. The key variables studied include wealth status, food security, and dietary behavior indicators at individual and household level. Household food insecurity access scale (HFIAS), livelihood coping strategies (LCS), food expenditure share (FES), food consumption score (FCS), household dietary diversity score (HDDS), minimum dietary diversity-women(MDD-W), and child dietary diversity score (CDDS) indicators were used to measure food security. Household assets were used to develop an asset-based wealth index that grouped the study sample population into five wealth quantiles, while income levels were used to estimate FES. The hypothesis that guided the cross-sectional survey conducted to generate these data is that vulnerability to food insecurity and poverty are important drivers of food choice that influence household and individual dietary behavior. Data from this study was thus used to assess direction and strength of association between; household food insecurity, wealth status, women, children, and household dietary behavior in both urban and peri‑urban populations sampled

How acceptable are antiretrovirals for the prevention of sexually transmitted HIV? A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention

Recent research has demonstrated how antiretrovirals (ARVs) could be effective in the prevention of sexually transmitted HIV. We review research on the acceptability of oral pre-exposure prophylaxis (PrEP) and treatment as prevention (TasP) for HIV prevention amongst potential users. We consider with whom, where and in what context this research has been conducted, how acceptability has been approached, and what research gaps remain. Findings from 33 studies show a lack of TasP research, PrEP studies which have focused largely on men who have sex with men (MSM) in a US context, and varied measures of acceptability. In order to identify when, where and for whom PrEP and TasP would be most appropriate and effective, research is needed in five areas: acceptability of TasP to people living with HIV; motivation for PrEP use and adherence; current perceptions and management of risk; the impact of broader social and structural factors; and consistent definition and operationalisation of acceptability which moves beyond adherence

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

Strategies to enhance the immunogenicity of DNA vaccines in humans include i) co-administration of molecular adjuvants, ii) intramuscular administration followed by in vivo electroporation (IM/EP) and/or iii) boosting with a different vaccine. Combining these strategies provided protection of macaques challenged with SIV; this clinical trial was designed to mimic the vaccine regimen in the SIV study.Seventy five healthy, HIV-seronegative adults were enrolled into a phase 1, randomized, double-blind, placebo-controlled trial. Multi-antigenic HIV (HIVMAG) plasmid DNA (pDNA) vaccine alone or co-administered with pDNA encoding human Interleukin 12 (IL-12) (GENEVAX IL-12) given by IM/EP using the TriGrid Delivery System was tested in different prime-boost regimens with recombinant Ad35 HIV vaccine given IM.All local reactions but one were mild or moderate. Systemic reactions and unsolicited adverse events including laboratory abnormalities did not differ between vaccine and placebo recipients. No serious adverse events (SAEs) were reported. T cell and antibody response rates after HIVMAG (x3) prime-Ad35 (x1) boost were independent of IL-12, while the magnitude of interferon gamma (IFN-γ) ELISPOT responses was highest after HIVMAG (x3) without IL-12. The quality and phenotype of T cell responses shown by intracellular cytokine staining (ICS) were similar between groups. Inhibition of HIV replication by autologous T cells was demonstrated after HIVMAG (x3) prime and was boosted after Ad35. HIV specific antibodies were detected only after Ad35 boost, although there was a priming effect with 3 doses of HIVMAG with or without IL-12. No anti-IL-12 antibodies were detected.The vaccines were safe, well tolerated and moderately immunogenic. Repeated administration IM/EP was well accepted. An adjuvant effect of co-administered plasmid IL-12 was not detected.ClinicalTrials.gov NCT01496989